中文摘要：

目的评价贝伐珠单抗联合同步放化疗在局部晚期头颈部鳞癌中的近期疗效及安全性。方法选取解放军总医院2014年10月-2015年10月初治局部晚期头颈部鳞癌患者40例,随机分为两组。实验组（贝伐珠单抗组）：先给予贝伐珠单抗＋2周期多西他赛联合顺铂诱导化疗,后行贝伐珠单抗＋螺旋断层调强放疗＋同步顺铂化疗;对照组：先给予2周期多西他赛联合顺铂诱导化疗,后行螺旋断层调强放疗＋同步顺铂化疗。结果实验组和对照组在治疗结束后3个月客观缓解率分别为100%（20/20）和80%（16/20）,差异有统计学意义（P=0.000 2）。除淋巴细胞减少外,大部分不良反应为1~2级,两组不良反应发生率差异无统计学意义（P〉0.05）。结论贝伐珠单抗联合同步放化疗治疗头颈部鳞癌安全有效。

英文摘要：

Objective To evaluate the clinical efficacy and safety of bevacizumab plus radiochemotherapy in treatment of locally advanced head and neck squamous carcinoma. Methods A total of 40 patients with locally advanced squamous carcinoma recruited from October 2014 to October 2015 in Chinese PLA General Hospital were randomly divided into two groups. Twenty patients in experimental group（bevacizumab group） received bevacizumab ＋ 2 cycles of docetaxel combined with cisplatin induction chemotherapy, following bevacizumab plus concomitant radiochemotherapy, and the other 20 patients in control group received same regimen as above but without bevacizumab. All patients in two groups underwent helical tomotherapy. Results The objective response rates in experimental group and control group were 100%（20/20） and 80%（16/20） after 3 months of therapy with significant difference（P =0.000 2）. In addition to lymphocyte reduction, most of acute toxicity was graded as 1 to 2 degree, with no significant difference between experimental group and control group（P 0.05）. Conclusion Bevacizumab combined with chemoradiotherapy is safe and effective in locally advanced head and neck squamous cell carcinoma.